Biocept Target Selector BRAF RUO Kits

Biocept has launched a Target Selector research-use-only molecular assay for the detection of BRAF mutations in both formalin-fixed, paraffin-embedded samples and blood samples. The kits use the company's Switch-Blocker technology to enrich the specimen for mutations of interest, resulting in ultra-high assay sensitivity and specificity. Biocept said that in general, its Target Selector kits can detect mutations of interest in circulating tumor DNA at a level of one mutant copy in 10,000 wildtype molecules. The assays can be used with a variety of analytical platforms including qPCR, Sanger sequencing, next generation sequencing, microarrays, and mass spectrometry. The new BRAF kit complements the company's previously launched EGFR mutation-detection assay.